Positron emission tomography (PET) in clinical oncology. Part II;Tomografía por emisión de positrones (PET) en oncología clínica (Parte II)

Revista Espanola de Medicina Nuclear

Volumn 21, Issue 2, 2002, Pages 131-147

  Cabrera Villegas, A ^a,c   Gamez Cenzano C ^b   Martin Urreta J C ^a  

^a Clin Vicente S Sebastian   (Spain)

^b Centro Andaluz de Diagnóstico PET   (Spain)

^c Unidad PET   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18; DIAGNOSTIC AGENT; FLUORINE; RADIOPHARMACEUTICAL AGENT;

CANCER LOCALIZATION; CANCER SCINTISCANNING; HUMAN; IMAGE ANALYSIS; LUNG CANCER; LYMPHOMA; MELANOMA; METASTASIS; ONCOLOGY; POSITRON EMISSION TOMOGRAPHY; REVIEW; ADULT; AGED; COLORECTAL TUMOR; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; LABORATORY DIAGNOSIS; LUNG TUMOR; LYMPH NODE; MALE; MIDDLE AGED; NEOPLASM; PREDICTION AND FORECASTING; RADIOGRAPHY; SCINTISCANNING; SENSITIVITY AND SPECIFICITY; TUMOR RECURRENCE;

ADULT; AGED; COLORECTAL NEOPLASMS; FALSE NEGATIVE REACTIONS; FALSE POSITIVE REACTIONS; FEMALE; FLUORINE RADIOISOTOPES; FLUORODEOXYGLUCOSE F18; HUMANS; LUNG NEOPLASMS; LYMPH NODES; LYMPHOMA; MALE; MELANOMA; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS; PREDICTIVE VALUE OF TESTS; RADIOPHARMACEUTICALS; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, EMISSION-COMPUTED; TOMOGRAPHY, X-RAY COMPUTED;

EID: 0036546540     PISSN: 02126982     EISSN: 1578200X     Source Type: Journal    
DOI: 10.1016/S0212-6982(02)72051-X     Document Type: Article

References (79)

1. Mack MJ, Hazelrigg SR, Landreneau RJ, Acuff TE. Thoracoscopy for the diagnosis of the indeterminate solitary pulmonary nodule. Ann Thorac Surg 1993;56:825-30.
2. Ginsberg RS, Vokes E, Raben A. Non-Small cell cancer of the lung. En: De Vita VT, Hellman S, Rsenberg SA (ed): cancer principles and practice of oncology. Philadelphia, PA, Lippincott-Raven. 1997. p. 858-911.
3. Patz EF, Erasmus JJ. Positron emission tomography imaging in lung cancer. Clinical Lung Cancer 1999;1:42-8.
4. Hubner KF, Buonocore E, Gould HR, Thie J, Smith GT, Stephens S, et al. Differentiating benign from malignant lung lesions using « quantitative» parameters of FDG PET images. Clin Nucl Med 1996;21:941-9.
5. Lowe VJ, Fletcher JW, Gobar L, Lawson M, Kirchner P, Valk P, et al. Prospective investigation of positron emission tomography in lung nodules. J Clin Oncol 1998;16:1075-84.
6. Gould MK, McLean CC, Kuschner WG, Rydzak CE, Owens DK. Accuracy of positron emission tomography for diagnosis of pulmonary nodules and mass lesions: a meta-analysis. JAMA 2001;285:914-24.
7. Slosman DO, Spiliopoulos A, Couson F, Nicod L, Louis O, Lemoine R, et al. Satellite PET and lung cancer: a prospective study in surgical patients. Nucl Med Commun 1993;14:955-61.
8. Higashi K, Ueda Y, Seki H, Yuasa K, Oguchi M, Noguchi T, et al. Fluorine-18-FDG PET imaging is negative in bronchioloalveolar lung carcinoma. J Nucl Med 1998;39:1016-20.
9. Kubota K, Matsuzawa T, Fujiwara T, Ito M, Hatazawa J, Ishiwata K, et al. Differential diagnosis of lung tumor with positron emission tomography: a prospective study. J Nucl Med 1990;31:1927-32.
10. Erasmus JJ, McAdams HP, Patz EF Jr, Coleman RE, Ahuja V, Goodman PC. Evaluation of primary pulmonary carcinoid tumors using FDG PET. AJR Am J Roentgenol 1998;170:1369-73.
11. Bakheet SM, Powe J. Benign causes of 18-FDG uptake on whole body imaging. Semin Nucl Med 1998;28:352-8.
12. Gould MK, Lillington GA. Strategy and cost in investigating solitary pulmonary nodules. Thorax 1998;53 Supl 2:S32-7.
13. Marom EM, Erasmus JJ, Patz EF. Lung cancer and positron emision tomoggraphy with fluorodeoxy-glucose. Lung Cancer 2000;28:187-202.
14. Kazeroomi EA, Lim FT, Mikhail A, Martínez F. Risk of neumothorax in CT-guided transthoracic needle aspiration biopsy of the lung. Radiology 1996;198:371-5.
15. Primack SL, Lee KS, Logan PM, Miller RR, Muller NL. Bronchogenic carcinoma: utility of CT in the evaluation of patients with suspected lesions. Radiology 1994;193:795-800.
16. McLoud TC, Bourgouin PM, Greenberg RW, Kosiuk JP, Templeton PA, Shepard JA, et al. Bronchogenic carcinoma: analysis of staging in the mediastinum with CT by correlative lymph node mapping and sampling. Radiology 1992;182:319-23.
17. Ihde DC, Pass HI, Glatstein E. Small cell lung cancer. En: Cancer: principles and Practice of Oncology. Vol I. De Vita VT, Hellman S, Rosenberg SA. 5th Ed. Philadelphia-New York. Lippincott-Raven, 1997. p. 911-49.
18. Dwamena BA, Sonnad SS, Angobaldo JO, Wahl RL. Metastases from non-small cell lung cancer: mediastinal staging in the 1990s-meta-analytic comparison of PET and CT. Radiology 1999;213:530-6.
19. Pieterman RM, van Putten JW, Meuzelaar JJ, Mooyaart EL, Vaalburg W, Koeter GH, et al. Preoperative staging of non-small-cell lung cancer with positron-emission tomography. N Engl J Med 2000;343:254-61.
20. Vansteenkiste JF, Stroobants SG, De Leyn PR, Dupont PJ, Bogaert J, Maes A, et al. Lymph node staging in non-small-cell lung cancer with FDG-PET scan: a prospective study on 690 lymph node stations from 68 patients. J Clin Oncol 1998;16:2142-9.
21. Gupta NC, Graeber GM, Bishop HA. Comparative efficacy of positron emission tomography with fluorodeoxyglucose in evaluation of small (<1 cm), intermediate (1 to 3 cm), and large (>3 cm) lymph node lesions. Chest 2000;117:773-8.
22. 18F]FDG positron emission tomography (PET). Thorax 1997;52:438-41.
23. Wahl RL, Quint LE, Greenough RL, Meyer CR, White RI, Orringer MB. Staging of mediastinal non-small cell lung cancer with FDG PET, CT, and fusion images: preliminary prospective evaluation. Radiology 1994;191:371-7.
24. Valk PE, Pounds TR, Hopkins DM, Haseman MK, Hofer GA, Greiss HB, et al. Staging non-small cell lung cancer by whole-body positron emission tomographic imaging. Ann Thorac Surg 1995;60:1573-82.
25. 18fluorine-fluorodeoxyglucose whole body positron emission tomography imaging in the staging of lung cancer. Ann Thorac Surg 1999;67:790-7.
26. Vansteenkiste JF, Stroobants SG, De Leyn PR, Dupont PJ, Verschakelen JA, Nackaerts KL, et al. Mediastinal lymph node staging with FDG-PET scan in patients with potentially operable non-small cell lung cancer: a prospective analysis of 50 cases. Chest 1997;112:1480-6.
27. Hoh CK, Schiepers C, Seltzer MA, Gambhir SS, Silverman DH, et al. PET in oncology: will it replace the other modalities? Semin Nucl Med 1997;27:94-106.
28. 18F-fluorodeoxyglucose positron emission tomography. AJR Am J Roentgenol 1997;168:1357-60.
29. 18FDG positron emission tomography in the staging of non-small cell lung cancer. Eur Respir J 1997;10:2529-34.
30. Farrell MA, McAdams HP, Herndon JE, Patz EF Jr. Non-small cell lung cancer: FDG PET for nodal staging in patients with stage I disease. Radiology 2000;215:886-90.
31. 18F-Fluoroethyl-L-Tyrosine with a small animal PET. J Nucl Med 2001;42 (Sup):280 P.
32. Okada J, Yoshikawa K, Itami M, Imaseki K, Uno K, Itami J, et al. Positron emission tomography using fluorine-18-fluorodeoxyglucose in malignant lymphoma: a comparison with proliferative activity. J Nucl Med 1992;33:325-9.
33. 18fluorine-fluorodeoxyglucose. Blood 1995;86:3522-7.
34. Rodríguez M, Rehn S, Ahlstrom H, Sundstrom C, Glimelius B. Predicting malignancy grade with PET in non-Hodgkin's lymphoma. J Nucl Med 1995;36:1790-6.
35. 67gallium citrate imaging for detection of lymphoma. J Nucl Med 1987;28:288-92.
36. Okada J, Yoshikawa K, Imazeki K, Minoshima S, Uno K, Itami J, et al. The use of FDG-PET in the detection and management of malignant lymphoma: correlation of uptake with prognosis. J Nucl Med 1991;32:686-91.
37. 67GA SPECT in Staging of Patients with Lymphoma. J Clin Oncol 2000;19:31.
38. 11C] Methionine and FDG. J Nucl Med 2000;41:1980-8.
39. Hoh CK, Glaspy J, Rosen P, Dahlbom M, Lee SJ, Kunkel L, et al. Whole-body FDG-PET imaging for staging of Hodgkin's disease and lymphoma. J Nucl Med 1997;38:343-8.
40. 18FDG PET and CT in pretherapeutic staging of malignant lymphoma. Nuklearmedizin, 1997;36:234-9.
41. 18F]fluoro-D-glucose (FDG) PET in nodal staging. Radiology, 1997;203:795-800.
42. Moog F, Bangerter M, Diederichs CG, Guhlmann A, Merklr E, Frickhofen N, et al. Extranodal malignant lymphoma: detection with FDG PET versus CT. Radiology 1998;206:475-81.
43. 18F-fluorodeoxyglucose-positron emission tomography as a new approach to detect lymphomatous bone marrow. J Clin Oncol. 1998;16:603-9.
44. Coiffier B, Gisselbrecht C, Vose JM, Tilly H, Herbrecht R, Bosly A, et al. Prognostic factors in aggressive malignant lymphomas: description and validation of a prognostic index that could identify patients requiring a more intensive therapy. The Groupe d'Etudes des Lymphomes Agressifs. J Clin Oncol 1991;9:211-9.
45. Canellos GP. Residual mass in lymphoma may not be residual disease. J Clin Oncol 1988;6:931-3.
46. 18fluorine-fluorodeoxyglucose scintigraphy. J Nucl Med 1993;34:1706-10.
47. Dimitrakopoulou-Strauss A, Strauss LG, Goldschmidt H, Lorenz WJ, Maier BW, Van Kaick G. Evaluation of tumor metabolism and multidrug resistance in patients with treated malignant lymphomas. Eur. J Nucl Med 1995;22:434-42.
48. Romer W, Hanauske AR, Ziegler S, Thodtmann R, Weber W, Fuchs C, et al. Positron emission tomography in non-Hodgkin's lymphoma: assessment of chemotherapy with fluorodeoxyglucose. Blood 1998;91:4464-71.
49. 18F-FDG uptake after a few cycles of polychemotherapy is predictive of treatment failure in non-Hodgkin's lymphoma. Haematologica 2000;85:613-8.
50. 18F]FDG-PET a valid alternative to conventional diagnostic methods? J Clin Oncol 2001;19:414-9.
51. 18F-FDG to detect residual disease after therapy for malignant lymphoma. Nucl Med Commun 1998;19:1055-63.
52. Cabrera A, Cánovas A, Martín Urreta JC. Neumonitis postradiación en un caso de Linfoma Hodgkin evaluado con PETFDG por masa mediastínica residual. Rev Esp Med Nucl 2000;19:288-92.
53. Balch CM, Murad TM, Soong SJ, Ingalls AL, Halpern NB, Maddox WA. A multifactorial analysis of melanoma: prognostic histopathological features comparing Clark's and Breslow's staging methods. Ann Surg 1978;188:732-42.
54. Gritters LS, Francis IR, Zasadny KR, Wahl RL. Initial assessment of positron emission tomography using 2-fluorine-18-fluoro-2-deoxy-D-glucose in the imaging of malignant melanoma. J Nucl Med 1993;34:1420-7.
55. Holder WD Jr, White RL Jr, Zuger JH, Easton EJ Jr, Greene FL. Effectiveness of positron emission tomography for the detection of melanoma metastases. Ann Surg 1998;227:764-9.
56. Damian DL, Fulham MJ, Thompson E, Thompson JF. Positron emission tomography in the detection and management of metastatic melanoma. Melanoma Res 1996;6:325-9.
57. 18F-fluorodeoxyglucose positron emission tomography: results of a prospective study of 100 patients. Cancer 1998;82:1664-71.
58. 18F]-2-deoxy-D-glucose positron emission tomography in staging of regional lymph nodes in patients with cutaneous malignant melanoma. J Clin Oncol 1998;16:1770-6.
59. Crippa F, Leutner M, Belli F, Gallino F, Greco M, Pilotti S, et al. Which kinds of lymph node metastases can FDG PET detect? A clinical study in melanoma. J Nucl Med 2000;41:1491-4.
60. rd, Saxman S, Hutchins G,et al. Prospective study of fluorodeoxyglucose-positron emission tomography imaging of lymph node basins in melanoma patients undergoing sentinel node biopsy. J Clin Oncol 1999;17:1508-15.
61. 18F FDG uptake in colonic adenoma. Clin Nucl Med 1998;23:99-100.
62. Falk PM, Gupta NC, Thorson AG, Frick MP, Boman BM, Christensen MA, et al. Positron emission tomography for preoperative staging of colorectal carcinoma. Dis Colon Rectum 1994;37:153-6.
63. Gupta NC, Falk PM, Frank AL, Thorson AM, Frick MP, Bowman B. Pre-operative staging of colorectal carcinoma using positron emission tomography. Nebr Med J 1993;78:30-5.
64. Baker ME, Pelley R. Hepatic metastases: basic principles and implications for radiologists. Radiology 1995;197:329-37.
65. Hollett MD, Jeffrey RB Jr, Nino-Murcia M, Jorgensen MJ, Harris DP. Dual-phase helical CT of the liver: value of arterial phase scans in the detection of small (< or = 1.5 cm) malignant hepatic neoplasms. AJR Am J Roentgenol 1995;164:879-84.
66. Schiepers C, Penninckx F, De Vadder N, Merckx E, Mortelmans L, Bormans G, et al. Contribution of PET in the diagnosis of recurrent colorectal cancer: comparison with conventional imaging. Eur J Surg Oncol 1995;21:517-22.
67. Gupta NC, Frank A, Mailliard, J et al. Accurace detection of liver metastases in patients with prymary malignancies using PET-FDG imaging. J Nucl Med 1993;34:6P.
68. 18F FDG PET in preoperative evaluation of patients with colon carcinima metastatic to liver. J Nucl Med 1995;36:106 P.
69. Hustinx R, Paulus P, Daenen F, et al. PET imaging of liver metastases: a retrospective study. J Nucl Med 1996;37:250 P.
70. Messa C, Choi Y, Hoh CK, Jacobs EL, Glaspy JA, Rege S, et al. Quantification of glucose utilization in liver metastases: parametric imaging of FDG uptake with PET. J Comput Assist Tomogr 1992;16:684-9.
71. Moertel CG, Fleming TR, MacDonald JS, Haller DG, Laurie JA, Tangen C. An evaluation of the carcinoembryonic antigen (CEA) test for monitoring patients with resected colon cancer. JAMA 1993;25,270:943-7.
72. Haberkorn U, Strauss LG, Dimitrakopoulou A, Engenhart R, Oberdorfer F, Ostertag H, et al. PET studies of fluorodeoxyglucose metabolism in patients with recurrent colorectal tumors receiving radiotherapy. J Nucl Med 1991;32:1485-90.
73. Balslev I, Pedersen M, Teglbjaerg PS, Hanberg-Soerensen F, Bone J, Jacobsen NO, et al. Postoperative radiotherapy in Dukes' B and C carcinoma of the rectum and rectosigmoid. A randomized multicenter study. Cancer 1986;58:22-8.
74. Gupta NC, Bowman BM, Frank AL, et al. PET-FDG imaging for follow-up evaluation of treated colorectal cancer. Radiology 1991;199:181 P.
75. 18F]fluorodeoxyglucose in recurrent colorectal cancer. Br J Surg 1994;81(11):1666-70.
76. Vitola JV, Delbeke D, Sandler MP, Campbell MG, Powers TA, Wright JK, et al. Positron emission tomography to stage suspected metastatic colorectal carcinoma to the liver. Am J Surg 1996;171:21-6.
77. Delbeke D, Vitola JV, Sandler MP, Arildsen RC, Powers TA, Wright JK Jr, et al. Staging recurrent metastatic colorectal carcinoma with PET. J Nucl Med 1997;38:1196-201.
78. 18F]fluorodeoxyglucose in management of recurrent colorectal cancer. Arch Surg 1999;134:503-11.
79. 18fluorine-2-fluoro-2-deoxy-D-glucose in recurrent colorectal cancer. J Clin Oncol 1999;17:894-901.